Results 11 to 20 of about 2,943 (200)

PBPK‐Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Treatment of breastfeeding mothers with malaria is challenging due to the lack of information describing drug exposure in milk and the daily dose to the breastfed infant.
Lisa M. Almond, Khaled Abduljalil, Amita Pansari, Beata Kusmider, Hannah M. Jones, Karen Rowland Yeo, Iain Gardner, Muhammad Faisal, Anne Claire Marrast, Myriam El Gaaloul, Jörg J. Möhrle, Nada Abla   +11 more
doaj   +3 more sources

Stimulation of Suicidal Erythrocyte Death by Tafenoquine

Cellular Physiology and Biochemistry, 2016
Background/Aims: The 8-aminoquinoline tafenoquine has been shown to be effective against Plasmodia, Leishmania and Trypanosoma. The substance is at least in part effective by triggering apoptosis of the parasites.
Abdulla Al Mamun Bhuyan, Rosi Bissinger, Katja Stockinger, Florian Lang   +3 more
doaj   +3 more sources

Tafenoquine for Relapsing Babesiosis: A Case Series. [PDF]

Clin Infect Dis
Abstract Background Relapsing babesiosis often occurs in highly immunocompromised patients and has been attributed to the acquisition of resistance against drugs commonly used for treatment such as atovaquone, azithromycin, and clindamycin.
Krause PJ, Rogers R, Shah MK, Kang H, Parsonnet J, Kodama R, Vannier E.   +6 more
europepmc   +4 more sources

Repurposing of the antimalarial agent tafenoquine to combat MRSA

mSystems, 2023
Staphylococcus aureus is an important human pathogen that often leads to hospital-acquired and community-acquired infections. The appearance of methicillin-resistant S. aureus (MRSA) has made the treatment extremely challenging.
Pengfei She, Yifan Yang, Linhui Li, Yimin Li, Shasha Liu, Zehao Li, Linying Zhou, Yong Wu   +7 more
doaj   +3 more sources

Assessing tafenoquine implementation in Brazil: a qualitative evaluation of perceptions of healthcare providers and Plasmodium vivax patients (QualiTRuST Study) [PDF]

Malaria Journal
Background To eliminate malaria by 2035, Brazil must address Plasmodium vivax. Previously, first-line treatment was chloroquine plus 7-day primaquine (PQ) without glucose-6-phosphate dehydrogenase (G6PD) deficiency testing.
Alicia P. C. Santos, Marcelo A. M. Brito, Ana P. S. Oliveira, Rafaela N. Dávila, Hiran S. S. Gama, Evellyn A. R. T. Silva, Hélio A. Amazonas Jr., Patrícia C. S. Balieiro, Rosilene Rufatto, Penny Grewal Daumerie, Cássio R. L. Peterka, Dhélio Batista Pereira, Marcus V. G. Lacerda, Felipe L. G. Murta   +13 more
doaj   +2 more sources

Tafenoquine: a toxicity overview [PDF]

Expert Opinion on Drug Safety, 2021
Introduction: A century-long history in 8-aminoquinolines, the only anti-malaria drug class preventing malaria relapse, has resulted in the approval of tafenoquine by the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) and to date registration in Brazil and Thailand.
Cindy S. Chu, Jimee Hwang
openaire   +2 more sources

Tafenoquine exhibits broad spectrum antifungal activity at clinically relevant concentrations in vitro and decreases lung fungal burden in an invasive pulmonary model of Rhizopus in vivo

New Microbes and New Infections, 2022
Background: Tafenoquine is active against a broad range of pathogens and accumulates extensively in the lung. We profiled the susceptibility of fungal pathogens to tafenoquine in vitro and in vivo.
G. Dow, B. Smith
doaj   +1 more source

Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with Acute Babesia microti Infection That Resulted in Rapid Clearance of Microscopically Detectable Parasitemia

Pathogens, 2023
Previous studies of mice infected with Babesia microti have shown that a single dose of tafenoquine administered orally is extremely effective at decreasing microscopically detectable parasitemia.
Dana G. Mordue, Synthia J. Hale, William E. Dennis, Chau V. Vuong, Xiu-Min Li, Nan Yang, Gary P. Wormser   +6 more
doaj   +1 more source

Malaria in Bangladesh, 2000-2025: Navigating the Headwinds From Control to Elimination. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Bangladesh has dramatically reduced its malaria burden since 2000, confining the disease to specific geographic zones. However, the national 2030 elimination goal is now threatened by a complex interplay of biological, ecological, and social factors.
Mamun AA, Kayenat MSA, Islam KAMI.
europepmc   +2 more sources

A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease

New Microbes and New Infections, 2022
The safety and efficacy of tafenoquine administered as a 200 mg dose once per day on days 1, 2, 3, and 10 was evaluated over a 28-day period in mild-moderate COVID-19 patients.
G.-S. Dow, B.-L. Smith
doaj   +1 more source